Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies.

Background: The advent of Antibody-Drug Conjugates (ADC) represents a significant advancement in targeted therapy for gynaecological malignancies. However, the ocular toxicities associated with ADCs, particularly Tisotumab Vedotin (TV) and Mirvetuximab Soravtansine (MIRV) necessitate effective mitigation in order to optimise patient care.

Methods: This review synthesises findings from clinical trials to delineate the spectrum of ocular adverse events induced by ADCs.